2026-05-23T07:05:25Zhttps://keep.lib.asu.edu/oai/request

oai:keep.lib.asu.edu:node-1937002024-12-23T18:01:48Zoai_pmh:repo_items

193700 https://hdl.handle.net/2286/R.2.N.193700 http://rightsstatements.org/vocab/InC/1.0/ All Rights Reserved 2024 2026-05-01T12:43:48 186 pages Doctoral Dissertation Academic theses Text eng Wilferd, Sierra Fe Plaisier, Christopher L Anderson, Karen Wilson, Melissa Hoang, Chuong D Arizona State University Partial requirement for: Ph.D., Arizona State University, 2024 Field of study: Biological Design Diffuse pleural mesothelioma (DPM) is a devastating lung cancer most commonly diagnosed at an advanced stage with a poor prognosis for patients. Therapies available to patients after diagnosis currently include surgical resection, radiotherapy, immunotherapy, and chemotherapy. However, these therapies only prolong life for about a year and a half on average. DPM patients desperately need effective therapies in the form of drugs, drug combinations, and miRNA-based therapies, that could lengthen overall survival and provide a better quality of life. I hypothesized that focusing on DPM tumor biology would streamline the process for discovering new therapies that will have a lasting impact for patients. I have applied systems biology methods to mine multiomic data from patient DPM tumors to discover new therapeutic options. I began by developing a somatic mutation integration pipeline, which created a comprehensive somatic mutational profile of DPM tumors from patient genomic and transcriptomic data. The somatic mutational profile was used in the generation of dpmSYGNAL, a disease-relevant gene regulatory network (GRN) trained on patient tumor multiomic data. I integrated this GRN with functional genomics screens performed on two low-passage primary DPM tumor cell lines and identified gene vulnerabilities that could be targeted by FDA-approved inhibitors and drug combinations. I also developed a pipeline to integrate miRNA target genes from biotinylated pulldowns with RNA-seq data from a study re-expressing the miRNA hsa-miR-497-5p in DPM cell lines. I determined that the re-expression of hsa-miR-497-5p had early pro-apoptotic effects and inhibited the cell cycle at later time points. The identification of inhibitors, combinations of inhibitors, and a therapeutic miRNA demonstrates that DPM biology can be used as a guide to discover new therapeutics for DPM. Bioengineering Drug Discovery Functional genomics gene regulatory network miRNA therapy somatic mutations Systems Biology Systems Biology Approaches to Discover Mesothelioma Therapies